These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Multiclass classification of FDG PET scans for the distinction between Parkinson's disease and atypical parkinsonian syndromes. Garraux G; Phillips C; Schrouff J; Kreisler A; Lemaire C; Degueldre C; Delcour C; Hustinx R; Luxen A; Destée A; Salmon E Neuroimage Clin; 2013; 2():883-93. PubMed ID: 24179839 [TBL] [Abstract][Full Text] [Related]
10. The Role of Tau Imaging in Parkinsonian Disorders. Hammes J; Drzezga A; van Eimeren T Curr Neurol Neurosci Rep; 2018 Oct; 18(12):86. PubMed ID: 30293094 [TBL] [Abstract][Full Text] [Related]
11. European Association of Nuclear Medicine and European Academy of Neurology recommendations for the use of brain Nobili F; Arbizu J; Bouwman F; Drzezga A; Agosta F; Nestor P; Walker Z; Boccardi M; Eur J Neurol; 2018 Oct; 25(10):1201-1217. PubMed ID: 29932266 [TBL] [Abstract][Full Text] [Related]
12. Clinical utility of FDG PET in Parkinson's disease and atypical parkinsonism associated with dementia. Walker Z; Gandolfo F; Orini S; Garibotto V; Agosta F; Arbizu J; Bouwman F; Drzezga A; Nestor P; Boccardi M; Altomare D; Festari C; Nobili F; Eur J Nucl Med Mol Imaging; 2018 Jul; 45(9):1534-1545. PubMed ID: 29779045 [TBL] [Abstract][Full Text] [Related]
13. PET Tau Imaging and Motor Impairments Differ Between Corticobasal Syndrome and Progressive Supranuclear Palsy With and Without Alzheimer's Disease Biomarkers. Vasilevskaya A; Taghdiri F; Multani N; Anor C; Misquitta K; Houle S; Burke C; Tang-Wai D; Lang AE; Fox S; Slow E; Rusjan P; Tartaglia MC Front Neurol; 2020; 11():574. PubMed ID: 32754109 [No Abstract] [Full Text] [Related]
14. FDG PET in the differential diagnosis of parkinsonian disorders. Eckert T; Barnes A; Dhawan V; Frucht S; Gordon MF; Feigin AS; Eidelberg D Neuroimage; 2005 Jul; 26(3):912-21. PubMed ID: 15955501 [TBL] [Abstract][Full Text] [Related]
15. Additive value of amyloid-PET in routine cases of clinical dementia work-up after FDG-PET. Brendel M; Schnabel J; Schönecker S; Wagner L; Brendel E; Meyer-Wilmes J; Unterrainer M; Schildan A; Patt M; Prix C; Ackl N; Catak C; Pogarell O; Levin J; Danek A; Buerger K; Bartenstein P; Barthel H; Sabri O; Rominger A Eur J Nucl Med Mol Imaging; 2017 Dec; 44(13):2239-2248. PubMed ID: 28932894 [TBL] [Abstract][Full Text] [Related]
16. Use of 11C-PE2I PET in differential diagnosis of parkinsonian disorders. Appel L; Jonasson M; Danfors T; Nyholm D; Askmark H; Lubberink M; Sörensen J J Nucl Med; 2015 Feb; 56(2):234-42. PubMed ID: 25593112 [TBL] [Abstract][Full Text] [Related]
17. More advantages in detecting bone and soft tissue metastases from prostate cancer using Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003 [TBL] [Abstract][Full Text] [Related]
18. Does corticobasal degeneration exist? A clinicopathological re-evaluation. Ling H; O'Sullivan SS; Holton JL; Revesz T; Massey LA; Williams DR; Paviour DC; Lees AJ Brain; 2010 Jul; 133(Pt 7):2045-57. PubMed ID: 20584946 [TBL] [Abstract][Full Text] [Related]
19. Diagnostic performance of 18F-fluorodeoxyglucose positron emission tomography in the evaluation of glioma. Shaw TB; Jeffree RL; Thomas P; Goodman S; Debowski M; Lwin Z; Chua B J Med Imaging Radiat Oncol; 2019 Oct; 63(5):650-656. PubMed ID: 31368665 [TBL] [Abstract][Full Text] [Related]
20. IBZM SPECT and FDG PET in the differential diagnosis of Parkinsonian syndromes: comparison with respect to inter-rater agreement. Derlin T; Afzal W; Wilke F; Apostolova I; Klutmann S; Meyer PT; Buhmann C; Hesse S; Buchert R Nuklearmedizin; 2010; 49(4):139-47. PubMed ID: 20502846 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]